Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma
- 22 February 2012
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 14 (4), 491-495
- https://doi.org/10.1093/neuonc/nos004
Abstract
Approximately 10% of patients with non-small cell lung cancer (NSCLC) have brain metastases at the time of diagnosis. When surgical resection is not possible, whole brain radiotherapy is the standard of care, with a cerebral response rate of approximately 30%. We report our experience with an upfront association of carboplatin and pemetrexed (areas under the curve, 5 and 500 mg/m(2), respectively), every 3 weeks, in 30 patients presenting with newly diagnosed brain metastases and NSCLC. Cerebral MRIs were performed every 6-9 weeks. The radiologic response rates were assessed according to Response Evaluation Criteria in Solid Tumors. Overall survival was also determined. Twenty-six patients were evaluable for response, and the objective cerebral response rate (complete and partial response) in the intent-to-treat population was 40% (12 of 30 patients). Event-free survival was 31 weeks, and median overall survival was 39 weeks. The upfront association of carboplatin plus pemetrexed allows simultaneous treatment of cerebral and systemic disease in patients with NSCLC with newly diagnosed brain metastases and appears to be particularly interesting in terms of radiologic response and overall survival. Further clinical studies are warranted.Keywords
This publication has 31 references indexed in Scilit:
- Activity of Pemetrexed on brain metastases from Non-Small Cell Lung CancerLung Cancer, 2010
- Pemetrexed in the treatment of advanced non-squamous lung cancerLung Cancer, 2009
- Prophylactic Cranial Irradiation in Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2007
- Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC studyAnnals of Oncology, 2006
- Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survivalInternational Journal of Radiation Oncology*Biology*Physics, 2006
- Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain MetastasesJournal of Clinical Oncology, 2006
- Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain MetastasesJournal of Clinical Oncology, 2003
- Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trialAnnals of Oncology, 2000
- Neurologic complications of systemic cancerDisease-a-Month, 1978